Cancer's sweet tooth for serine by Luo, Ji
Recent advances in understanding the metabolic altera-
tions in cancer cells have shed light on how tumors fuel 
rapid growth by preferentially engaging biosynthetic 
pathways [1,2]. Although cellular metabolic pathways are 
rich pickings for drug targets, pin-pointing enzymes that 
critically contribute to tumor metabolism is key to estab-
lishing a therapeutic window since most of meta  bolic 
enzymes also play important roles in normal tissues.
Two recent studies explored the landscape of tumor 
metabolism using diﬀ   erent approaches, yet both 
identiﬁ  ed the enzyme phosphoglycerate dehydrogenase 
(PHGDH) to be critical for the viability of a subset of 
breast cancer cells that overexpress this enzyme [3,4]. 
Possemato and colleagues conducted an elegant in vivo
shRNA drop-out screen to identify metabolic pathways 
that might be diﬀ  erentially required for the viability of 
cancer cells. Th   e authors transduced a lentiviral shRNA 
library targeting 133 metabolic enzymes and metabolite 
transporters into the human breast cancer cell line 
MCF10DCIS.COM [3]. Th  ese cells were then injected 
into mice to establish xenograft tumors. By analyzing 
which shRNAs dis  appeared from the library in the 
tumors, they were able to infer several metabolic genes to 
be necessary for the growth of tumor cells in vivo. 
PHGDH is among the several genes identiﬁ   ed in this 
screen.
Locasale and colleagues homed in on PHGDH from a 
diﬀ  erent angle. By analyzing glucose ﬂ  ux in the trans-
formed HEK293T cells, they found a high ﬂ  ux of glucose 
towards glycine production that can be attributed to the 
serine biosynthetic pathway [4]. PHGDH is the ﬁ  rst 
enzyme in this pathway that diverts glucose from 
glycolysis to serine production.
By analyzing cancer CGH and gene expression data, 
both groups noted that PHGDH is ampliﬁ  ed or over-
expressed in a subset of melanoma and breast cancers. In 
breast cancer, elevated PHGDH is more frequently found 
in estrogen receptor-negative and basal-like tumors. 
Strikingly, whereas RNAi-mediated depletion of PHGDH 
has little eﬀ  ect on the viability of untransformed breast 
epithelial cells or breast cancer cells without PHGDH 
ampliﬁ  cation/overexpression, depleting PHGDH strongly 
inhibited the proliferation of a panel of breast cancer cells 
where PHGDH is ampliﬁ  ed or overexpressed. Th  is  latter 
group of cells thus exhibit functional addiction to 
PHGDH. Furthermore, using an inducible PHGDH 
shRNA in the breast cancer MDA-MB-468 cells (which 
carry PHGDH ampliﬁ  cation), Possemato and colleagues 
showed that depletion of PHGDH also inhibited tumor 
growth in vivo [3].
PHGDH catalyzes the ﬁ   rst step in the serine bio-
synthetic pathway (Figure  1). Th  is pathway diverts a 
relatively small fraction (<10%) of 3-phosphoglycerate 
from glycolysis to generate serine as well as equimolar 
amounts of reduced nicotinamide adenine dinucleotide 
and α-ketoglutarate. Indeed, Possemato and colleagues 
showed that two other enzymes in this pathway, PSAT1 
and PSPH, also have higher expres  sion in estrogen 
receptor-negative breast tumors, and RNAi knockdown 
of PSAT1 and PSPH selectively impaired the viability of 
breast cancer cells harboring PHGDH ampliﬁ  cation [3].
So do tumor cells with high levels of PHGDH need 
more serine for growth? Here the answer becomes more 
complicated. Locasale and colleagues found higher levels 
of PHGDH were associated with higher serine produc-
tion in melanoma cells and, conversely, that RNAi 
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Exemplifi  ed by the cancer cell’s preference for 
glycolysis (the Warburg eff  ect), altered metabolism has 
taken centerstage as an emerging hallmark of cancer. 
Charting the landscape of cancer metabolic addictions 
should reveal new avenues for therapeutic attack. Two 
recent studies found subsets of human melanoma and 
breast cancers to have high levels of phosphoglycerate 
dehydrogenase (PHGDH), a key enzyme for serine 
biosynthesis, and these cancer cells are dependent on 
PHGDH for their growth and survival. Tumors may thus 
harbor distinct metabolic alterations to support their 
malignancy, and targeting enzymes such as PHGDH 
might prove a viable therapeutic strategy in this 
scenario.
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On the other hand, Possemato and colleagues noted that 
breast cancer cells with high levels of PHGDH are 
resistant to serine withdrawal and their loss of viability 
upon PHGDH knock  down cannot be rescued by 
supplemental serine. Instead, the depletion of PHGDH in 
breast cancer cells leads to a decrease in the level of α-
ketoglutarate, a key biosynthetic precursor in the citric 
acid cycle. However, loss of α-ketoglutarate upon 
PHGDH depletion was not observed in melanoma cells 
by Locasale and colleagues. Th  e same addiction to 
PHGDH therefore might manifest as distinct metabolite 
addictions – some cell lines might require serine, others 
α-ketoglutarate, and still others reduced nicotinamide 
adenine dinucleotide. Indeed, metabolic proﬁ  ling showed 
that the levels of many metabolites are altered upon 
PHGDH knockdown.
Intriguingly, PHGDH overexpression might directly 
promote oncogenesis. Using the MCF-10A breast epi  the-
lial cell morphogenesis assay in 3D matrigel, Locasale 
and colleagues showed that overexpression of PHGDH in 
these cells increased their proliferation rate and disrupted 
the acinar structure of these cells. A change in cellular 
serine metabolism could thus directly lead to altered 
phenotypic behavior that favors transformation. 
Understanding how this happens would shed new light 
on the metabolic mechanisms of oncogenesis.
Th   e studies by Possemato and colleagues and Locasale 
and colleagues strongly implicate PHGDH as an 
attractive drug target in the subset of tumors that amplify 
or overexpress this gene. As PHGDH-dependent serine 
biosynthesis operates in all cells, it would be important to 
determine whether a suﬃ   cient  therapeutic  window 
exists. Congenital mutations in PHGDH have been docu-
mented in humans and result in serine deﬁ  ciency dis-
orders. Th   e main manifestation of this disorder is severe 
neurological symptoms of the central nervous system as 
serine does not cross the blood–brain barrier and 
consequently neurons and glial cells entirely rely on de 
novo serine synthesis [5]. Similar central nervous system 
disorders have been observed in PHGDH knockout mice 
[6]. Despite these manifestations, PHGDH inhibition 
remains a viable cancer therapeutic strategy for two 
reasons. First, a PHGDH inhibitor designed not to cross 
the blood–brain barrier would not interfere with serine 
homeostasis in the central nervous system, thus avoiding 
Figure 1. Serine biosynthetic pathway. In vivo shRNA lethality screen and metabolomic profi  ling independently identifi  ed 3-phosphoglycerate 
dehydrogenase (PHGDH) to be essential in a subset of cancer cells that overexpress this enzyme. PHGDH plays a key role in serine biosynthesis, 
and cancer cells with high PHGDH activity might be addicted to this pathway for their viability. αKG, α-ketoglutarate; NADH, reduced nicotinamide 
adenine dinucleotide; PSAT1, phosphoserine aminotransferase 1; PSPH, phosphoserine phosphatase; TCA, tricarboxylic acid.
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Page 2 of 3potential neurological side eﬀ   ects. Second, serine 
deﬁ  ciency disorders can be treated by exogenous serine 
supplement, whereas tumors’ addiction to PHGDH 
might not be associated with serine ﬂ   ux. A PHGDH 
inhibitor that is non-permeable to the central nervous 
system coupled with serine supplement might thus 
provide the therapeutic index needed to selectively target 
tumor cells.
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